The Administrative Core for this specific Northwest Prostate Cancer SPORE will consists of a variety of interacting committees working closely with the PI (Peter Nelson, M.D.), Co-Pi (Paul Lange, M.D.) and Co-Pi (Janet Stanford, Ph.D.). The administrative staff consists of personnel trained in finance, grants management, clinical research support, and education/editorial services. The committees will involve: 1. External and Internal advisory boards consisting of outside and inside experts (both MDs and PhD1s, some of which are already prostate cancer SPORE directors) who will advise the PPs on the scientific progress and direction of the SPORE; 2. A scientific working committee consisting of four senior members of the SPORE who will oversee the """"""""daily"""""""" administrative issues of the SPORE; 3. A conference and educational committee which will plan and conduct extensive educational and mentoring activities for the SPORE; 4. A Career Development Committee which will oversee the recruitment, selection, and training of the SPORE Fellows and coordinate the participation of over 20 research mentors. This committee will also assist the scientific working committee and executive committee in soliciting and selecting new innovation pilot research projects; 5. A Translational Committee consisting of SPORE and outside clinicians and translational researchers whose specific task is to assess the translational progress of the SPORE and suggest new avenues for translational research; 6. An Advocacy Committee consisting of professional and business prostate cancer survivors whose major function will be to assess the progress and public image of the SPORE and suggest new avenues for inquiry, and to enhance institutional and community support for SPORE activities, concerns, and needs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097186-06
Application #
7314942
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-09-14
Budget End
2008-06-30
Support Year
6
Fiscal Year
2007
Total Cost
$229,768
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Dai, James Y; Wang, Bo; Wang, Xiaoyu et al. (2018) Vigorous physical activity is associated with metastatic-lethal progression in prostate cancer and differential tumor DNA methylation in the CRACR2A gene. Cancer Epidemiol Biomarkers Prev :
Mateo, Joaquin; Cheng, Heather H; Beltran, Himisha et al. (2018) Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol 73:687-693
Lim, Daniel M; Gulati, Roman; Aleshin-Guendel, Serge et al. (2018) Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. Prostate :
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
FitzGerald, L M; Zhao, S; Leonardson, A et al. (2018) Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis 21:228-237
Lee, Chung C W; Munuganti, Ravi Shashi Nayana; Peacock, James W et al. (2018) Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. J Endocr Soc 2:1381-1394
Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :
Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216
Bello, Thomas; Gujral, Taranjit S (2018) KInhibition: A Kinase Inhibitor Selection Portal. iScience 8:49-53

Showing the most recent 10 out of 400 publications